Louise Frederika Kooij, the Chief Accounting Officer of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), has recently sold a total of 45,000 ordinary shares of the company, according to a new SEC filing. The transaction, which took place on October 1, 2024, was executed at a price of $15.72 per share, resulting in a total sale value of $707,400.
The sale followed an acquisition of the same number of shares on September 27, 2024, which were previously held indirectly through LouFre Management B.V. for the benefit of Kooij. The shares were acquired at an exercise price of EUR 1.16392, as noted in the footnotes of the SEC filing.
This move reduced Kooij's direct holdings in NewAmsterdam Pharma to zero, as indicated in the post-transaction amounts. The filing also mentioned options granted to Kooij, with an exercise price equivalent to EUR 1.16392 and an expiration date of July 6, 2031. A portion of these options had vested on the grant date, with additional vesting occurring on a monthly basis contingent upon continued service.
Investors and market watchers often keep a close eye on insider transactions such as these for insights into executive sentiment toward their company's stock. Although the reasons behind Kooij's sale are not disclosed in the filing, the transaction is part of the public record for stakeholders to consider.
NewAmsterdam Pharma, a pharmaceutical company with a focus on life sciences, is known for its work in the pharmaceutical preparations sector. Executives' dealings in the company's shares are routinely disclosed in compliance with SEC regulations, providing transparency into the financial activities of its key personnel.
In other recent news, NewAmsterdam Pharma Co NV has reported positive outcomes from its Phase 3 BROOKLYN clinical trial. The drug candidate, Obicetrapib, demonstrated a significant reduction in low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia. The company is set to release top-line data from this trial, assessing Obicetrapib's efficacy for patients with elevated cholesterol levels unresponsive to existing treatments.
Analysts from Piper Sandler and TD Cowen have maintained positive ratings on NewAmsterdam's stock, citing the potential of Obicetrapib and upcoming data releases. Piper Sandler emphasized the low clinical risk associated with the company, while TD Cowen expressed confidence in the drug's potential to improve patient health outcomes.
Furthermore, NewAmsterdam recently expanded its board of directors, welcoming Mark C. McKenna and Wouter Joustra. This strategic move coincides with the company's anticipation of pivotal Phase 3 data readouts from ongoing clinical trials. These are the recent developments for NewAmsterdam Pharma Co NV.
InvestingPro Insights
To complement the recent insider transaction at NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), InvestingPro data offers additional context for investors. The company's market capitalization stands at $1.55 billion, reflecting its current valuation in the pharmaceutical sector.
Despite the recent share sale by the Chief Accounting Officer, InvestingPro Tips highlight that NAMS holds more cash than debt on its balance sheet, indicating a strong financial position. This liquidity strength is further supported by the fact that the company's liquid assets exceed short-term obligations, which could provide flexibility for future operations and investments.
However, it's important to note that NAMS is not currently profitable, with a negative P/E ratio of -7.74 for the last twelve months as of Q2 2024. This aligns with another InvestingPro Tip suggesting that analysts do not anticipate the company to be profitable this year. The company's revenue for the same period was $7.42 million, with a significant revenue growth decline of -32.3% year-over-year.
On a positive note, NAMS has shown a high return over the last year, with a one-year price total return of 79.46% as of the latest data. This performance is particularly noteworthy given the challenging environment for many pharmaceutical companies.
For investors seeking a more comprehensive analysis, InvestingPro offers additional tips and metrics beyond those mentioned here. In fact, there are 5 more InvestingPro Tips available for NAMS, which could provide further insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.